CPIC 2026 | Nanobody Drug R&D Session Agenda Released
Update time:
2026-05-19 13:11
Reads:
Small in size, powerful in function, nanobodies are reshaping the R&D paradigm of biopharmaceuticals. The full agenda of the Nanobody Drug R&D Session, co organized by Biointron, is unveiled today.
This session brings together pioneers in the nanobody sector to systematically dissect key links across the entire nanobody drug development chain — from hit discovery and engineering design, to druggability evaluation and large scale manufacturing. Join industry trailblazers in Shanghai, July 22–24, to discuss the future of nanobodies.
Special Session Agenda
Co-organizer: BioEngine
Opening Remarks
Changchun Zha：Chairman, Biointron
Progress of Nanobody‑based Therapeutics & Applications in ADCs
Haikun Shi: Founder & Chairman, Kunyu Biotech
Development of Nanobody Therapeutics for Diabetic Nephropathy
Jiajun Fan: Director & Principal Investigator, Institute of Biotech Pharmaceuticals, Quzhou Fuda Biomedical Innovation Institute; Shanghai Rising Star Young Scientist
Dual Epitope Nanobodies for Acute Disease Therapy Strategies
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Applications of Diverse Screening Platforms in Nanobody Discovery
Lei Shi: Senior Vice President, Biointron
Roundtable: Challenges and Future of Next‑Generation Antibody Drugs
Moderator: Haikun Shi: Founder & Chairman, Kunyu Biotech
Shuqing Chen: Professor & Doctoral Supervisor, College of Pharmaceutical Sciences, Zhejiang University; Founder & Chairman, Neoantigen
Jun Wang: General Manager,Jushi Biotech,CSPC Pharmaceutical Group
Tao Xu: Founder & CEO, SmartNuclide
Jing Huang: COO & CBO, Novamab
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Related News
Contact us
Address：Room 62, 6th Floor, Building 1, Zone 1, No.186 South 4th Ring West Road , Fengtai District, Beijing
Tel：010-83634390
Address：Address：Room 1704, Building E, Nanotechnology Park, SIP, Suzhou, Jiangsu Province
TONACEA
XIEYI Release
TONACEA Biotech
TONACEA Micro Service
